SEQ_NO | 2 | Date of announcement | 2024/10/24 | Time of announcement | 23:34:05 |
Subject | Announcement of the press release content for the company’s major news conference held today |
||||
Date of events | 2024/10/24 | To which item it meets | paragraph 53 | ||
Statement | 1.Date of occurrence of the event:2024/10/24 2.Company name:Microbio Co., Ltd. 3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):head office 4.Reciprocal shareholding ratios:NA 5.Cause of occurrence: On October 24, 2024, the Company’s Board of Directors approved to acquire the stock shares of Onenessbio Co., Ltd. from Diamond Biofund Inc. within the quota of NT$1 billion. 6.Countermeasures: The company will hold a major news press conference at Taipei Exchange to explain the case at 10 pm on October 24, 2024. The press release is as follows: Upon resolution of the Audit Committee and the Board of Directors, Microbio Co., Ltd. will acquire the stocks of Oneness Biotech Co., Ltd. from Diamond Biofund Inc. through a paired block trade within the quota of NT$1 billion. This transaction is expected to obtain up to 8,000,000 shares. The final trading price per share will be the same for the international institutional investors who join the block trade of Oneness Biotech Co., Ltd. shares held by Diamond Biofund Inc. Oneness Biotech Co., Ltd. is an “Equity Method” related company of Microbio Co., Ltd.. The original holdings are 19.67%. Oneness Biotech Co., Ltd. has recently continued to make breakthroughs in operations. In addition to the global commercialization of the diabetic foot ulcer new drug, a nucleic acid new drug SNS812 for treating COVID-19 variants infection also succeeded in the Phase II trial. Moreover, there are the “happily slim” weight loss new drug SNS851 and two first-in-class anti-infection small nucleic acid new drugs, SNS611 and SNS612. It has the potential to become a globally competitive nucleic acid new drug company. The company is optimistic that Oneness Biotech’s future revenue and licensing will gradually increase, and its profits will have high growth potential, which can contribute to the company’s reinvestment profit growth. Therefore, through this opportunity that Diamond Biofund releases Oneness Biotech stocks, Microbio Co., Ltd. uses its funds within the limits of reinvestment stipulated by regulations through a paired block trade to increase the holdings of Oneness Biotech, which will be around 21% after the trade. 7.Any other matters that need to be specified(the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.):None |
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.